Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Buy rating on the stock and has a $8.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Naz Rahman has given his Buy rating due to a combination of factors that highlight Cingulate Inc.’s promising position in the biotechnology sector. The company’s lead asset, CTx-1301, is in the advanced stages of development for treating ADHD, with the FDA having accepted its NDA application. This acceptance, along with a PDUFA date set for May 31, 2026, positions Cingulate well for potential market entry, especially considering the current stimulant shortages.
Additionally, Cingulate’s strategic partnership with Indegene, a company with over two decades of experience in pharmaceutical commercialization, is expected to bolster the launch of CTx-1301. The hiring of Bryan Downey as Chief Commercial Officer, who brings extensive experience in pharmaceutical product launches, further strengthens their pre-commercial efforts. These strategic moves, combined with the innovative Precision Timed Release technology of CTx-1301, which offers a competitive edge in terms of onset and duration, underpin Rahman’s optimistic outlook and Buy rating for Cingulate Inc.